42302-16-9

Usage

Uses

Used in Organic Synthesis:
2-(pyrrolidin-1-yl)ethanethiol is used as a building block in organic synthesis for creating more complex molecules, leveraging its unique structural features to enhance the properties and functions of the resulting compounds.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
In the field of asymmetric synthesis, 2-(pyrrolidin-1-yl)ethanethiol is employed as a chiral auxiliary to control the stereochemistry of reactions, ensuring the production of enantiomerically pure compounds, which is crucial for the development of pharmaceuticals and other chiral molecules.
Used in Pharmaceutical and Medicinal Chemistry:
2-(pyrrolidin-1-yl)ethanethiol is studied for its potential therapeutic applications in the pharmaceutical and medicinal chemistry industries, where its unique properties may contribute to the discovery and development of new drugs and therapeutic agents.
Used in Chemical Industry:
2-(pyrrolidin-1-yl)ethanethiol is utilized across various sectors of the chemical industry for its diverse applications, including but not limited to the synthesis of specialty chemicals, development of new materials, and enhancement of existing products through its unique reactivity and structural attributes.

Upstream product

• 420-12-2 thirane 
• 123-75-1 pyrrolidine 

Downstream Products

• 5411-36-9 diphenyl-thioacetic acid S-(2-pyrrolidino-ethyl ester); hydrochloride 
• 1226861-38-6 5-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)methyl]-2-{[2-(pyrrolidin-1-yl)ethyl]sulphanyl}pyridine 
• 1226861-64-8 5-[5-Methyl-1-(4-{[2-(pyrrolidin-1-yl)ethyl]sulphanyl}benzyl)-1H-pyrazol-3-yl]-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole 
• 193963-59-6 (2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophen-3-yl)-(4-[[2-(1-pyrrolidinyl)ethyl]thio]phenyl)ketone 
• 1042777-99-0 5-(2-pyrrolidin-1-yl-ethylsulfanyl)-thiazol-2-ylamine 

Relevant academic research and scientific papers

Strained metal bonding environments in methylindium dithiolates and their reactivity as initiators for the ring-opening polymerization of cyclic esters

We have synthesized indium complexes containing a variety of metal bonding environments through use of polyfunctional dithiolate ligands and examined their reactivity as initiators for the ring-opening polymerization of l-lactide, rac-lactide, ?-caprolactone and β-butyrolactone. The facile reaction of Me3In with the corresponding polyfunctional dithiols in toluene, thf or diethyl ether resulted in the formation of [MeIn(SOOS)]2 (3), MeIn(SNNS) (4), [MeIn(ONS2)]3 (5), MeIn(NNS2) (6), MeIn(NNS2Pr) (7) and MeIn(pyrS)2 (8). The solid-state structures of 3 and 5 each show the corresponding ligand to be tridentate with an uncoordinated ligand O atom. Dimeric (3) and trimeric (5) structures result from short intermolecular In ... S interactions. All structures show five coordinate indium centres in distorted trigonal bipyramidal bonding environments, but with various arrangements of donor atoms (eq/ax): SSC/OS (3,5), SNC/NS (4), SSN/NC (6), SSC/NS (7) and SSC/NN (8). DFT studies of model MeIn(SMe)2(NH3)2 systems show the bonding environments in 4 and 6 to be highly strained, while the axial In-Me bond of 6 shows the longest bond distance and lowest vibrational frequency. Compound 5 provided the best control of the polymerization of l-lactide and rac-lactide in THF at 70°C, and a small heterotactic enrichment was observed for the latter. Compounds 3 and 4 provided the best control of the polymerization of β-BL in toluene at 70°C in toluene, and compound 3 provided the best control of the polymerization of ?-CL in toluene at 70°C. In all cases, polymerization rates were low. This work demonstrates a systematic approach to exploring the modification and reactivity of main group metal bonding motifs, which has resulted in identification of two novel "strained" bonding environments for indium.

LIPOCATIONIC POLYMERS AND USES THEREOF

Polymers produced by ring opening polymerization which comprises an amino group that can be used in compositions to deliver a nucleic acid such as a miRNA or a siRNA. In some embodiments, compositions which comprise the polymers described herein and a nucleic acid are also provided herein. In some embodiments, these compositions are used to silence one or more genes in vivo or treat a disease or disorder.

Rapid Synthesis of a Lipocationic Polyester Library via Ring-Opening Polymerization of Functional Valerolactones for Efficacious siRNA Delivery

The ability to control chemical functionality is an exciting feature of modern polymer science that enables precise design of drug delivery systems. Ring-opening polymerization of functional monomers has emerged as a versatile method to prepare clinically translatable degradable polyesters.1 A variety of functional groups have been introduced into lactones; however, the direct polymerization of tertiary amine functionalized cyclic esters has remained elusive. We report a strategy that enabled the rapid synthesis of >130 lipocationic polyesters directly from functional monomers without protecting groups. These polymers are highly effective for siRNA delivery at low doses in vitro and in vivo.

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.

Aryl compounds with aminoalkyl substituents and their use

The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

CYCLOPROPYL COMPOUNDS

A compound of the formula: and pharmaceutical compositions for the treatment of diabetes.

Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs

Quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs (NSAIDs) are disclosed. These esters and thioesters display the anti--inflammatory profile of the parent NSAIDs with greatly reduced gastrointestinal irritancy, providing a more favorable separation of therapeutic activity and toxicological side effects than the parent NSAIDs.

Pristinamycin derivatives, their preparation and their use

The invention provides new pristinamycin IIB derivatives of the formula: STR1 in which R represents alkylthio substituted by (i) alkylamino or dialkylamino of which the alkyl parts can form a pyrrolidin-1-yl, piperidino, azetidin-1-yl, azepin-1-yl, morpholino, thiomorpholino or piperazin-1-yl ring (optionally substituted by alkyl), or (ii) pyrrolidin-2-yl or pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl or piperidin-4-yl, azetidin-2-yl or azetidin-3-yl or azepin-2-yl, azepin-3-yl or azepin-4-yl; a radical Het-S-, in which Het is pyrrolidin-3-yl, piperidin-3-yl or piperidin-4-yl, azetidin-3-yl or azepin-3-yl or azepin-4-yl optionally N-alkylsubstituted; or dialkylamino of which the alkyl parts can form a pyrrolidin-1-yl, piperidino, azetidin-1-yl, azepin-1-yl, morpholino, thiomorpholino or piperazin-1-yl ring (optionally substituted by alkyl), the said alkyls having 1 to 5 carbon atoms each in a linear or branched chain. The compounds of the formula (I) are useful as antimicrobial agents when used in association with known synergistines or synergistines of the formula: STR2

Synergistine derivatives having anti-bacterial activity and their use

The invention provides new synergistine derivatives of the formula: STR1 in which Y=H or N(CH3)2 and (a) R1 and R2 =H and R=pyrrolidin-3-ylthio or piperidin-3-ylthio or piperidin-4-ylthio (optionally substituted by alkyl), or altenatively R=alkylthio substituted by 1 or 2 SO3 H radicals or alkylamino or dialkylamino radicals (optionally substituted) or by 1 or 2 piperazino rings (optionally substituted) or morpholino, thiomorpholino, piperidino, pyrrolidin-1-yl, piperidin-2-yl, piperidin-3-yl or piperidin-4-yl or pyrrolidin-2-yl or pyrrolidin-3-yl rings (these last 5 rings being optionally substituted by alkyl), or (b) R1 and R2 form a bond and R=pyrrolidin-3-ylamino, piperidin-3-ylamino or piperidin-4-ylamino, pyrrolidin-3-yloxy, piperidin-3-yloxy or piperidin-4-yloxy, pyrrolidin-3-ylthio, piperidin-3-ylthio or piperidin-4-ylthio (optionally substituted by alkyl), or alternatively R=alkylamino, alkoxy or alkylthio substituted by 1 or 2 SO3 H radicals, alkylamino or dialkylamino radicals (optionally substituted) or trialkylammonio or imidazol-4-yl or imidazol-5-yl radicals or by 1 or 2 piperazino rings (optionally substituted by alkyl) or morpholino, thiomorpholino, piperidino, pyrrolidin-1-yl, piperidin-2-yl, piperidin-3-yl or piperidin-4-yl or pyrrolidin-2-yl or pyrrolidin-3-yl rings (these last two rings being optionally substituted by alkyl), and their salts, their preparation, and the pharmaceutical compositions in which they are present. These compounds are useful as anitbacterial agents.

Synergistine derivatives and their preparation

The invention provides new synergistine derivatives of the formula: STR1 in which Y=H or N(CH3)2 and R represents: (a) H or OH, (b) a radical of the formula NR1 R2, in which R1 and R2 =H, phenyl or pyridyl (optionally substituted by dialkylamino (1 to 4 C), alkyl (1 to 10 C) [optionally substituted by OH, SH, COOH, anilino, or alkylamino or dialkylamino of which at least one of the alkyl parts is substituted by OH, SH, COOH or anilino 9 , alkenyl (3 or 4 C) or alkynyl (3 or 4 C), or alternatively R1 and R2 together form a heterocycle optionally containing another heteroatom such as O, S or N (optionally substituted by alkyl), or (c) a halogen atom, a trimethylsilyloxy or dialkylphosphoryloxy radical or a radical --OSO2 R3 or --OCOR4, R3 being alkyl, trifluoromethyl, trichloromethyl or optionally substituted phenyl and R4 being defined in the same way as R3 or being an acylalkyl, alkoxycarbonylalkyl or alkoxy radical, and also their salts and their preparation. These products are useful as intermediates in the synthesis of anti-bacterial synergistine derivatives.